Novocure partners with Stanford School of Medicine to begin research on new cancer therapy
Novocure’s partnership with Stanford is the oncology company’s latest development in developing some of the most innovative therapies for treating aggressive forms of cancer. Its pioneering treatment, Tumor Treating Fields (TTFields), exerts forces to target cancer cells without significantly impacting healthy cells due to their different physical properties. Furthermore, preclinical trials indicate that TTFields can be combined with other cancer therapies to improve a patient’s prognosis. The partnership will expedite preclinical and clinical trials of Novocure’s inovitro™, inovitro Live™ and inovivo™ TTFields systems. Novocure celebrated the agreement, citing Stanford Medicine’s participation in TRIDENT, a multi-center study of TTFields therapy in glioblastoma (GBM) patients.
“We look forward to collaborating with Stanford Medicine to establish a research framework for preclinical and clinical development of TTFields,” said Moshe Giladi, Ph.D., Novocure’s Chief Science Officer. “Together, we will enable new discoveries into the mechanisms and treatment possibilities of TTFields, including new indications and uses of TTFields and other therapies. We will pursue our mission to extend survival in some of the most aggressive forms of cancer while enhancing the education and scholarship of future clinicians and scientists.”
The New England Council congratulates Novocure on its partnership with Stanford Medicine.
Read more in the official Novocure press release.